ET50 mg | Epithalon | 99% White powder High Quality semaglutide weight CAS NO. 149714-25-0
TDS
149714-25-0
High Purity Grade
99%
Shenzhen
Tong Peptides
50mg/vial, 10 vials/box
2027-04-14
retatrutide,TB-500,GHK-CU,peptide
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial Reference5-diphospho-1D-myo-inositol pentakisphosphate is a myo-inositol pentakisphosphate that consists of 1D-myo-inositol having the five phospho groups located at positions 1, 2, 3, 4 and 6 as well as a diphospho group at position 5. It has a role as a human metabolite. It derives from a myo-inositol. It is a conjugate acid of a 5-diphospho-1D-myo-inositol pentakisphosphate(13-).CertificatesBasic Info
-
Product Name:
diphosphoric acid, mono[(1alpha,2beta,3alpha,4alpha,5alpha,6beta)-2,3, 4,5,6-pentakis(phosphonooxy)cyclohexyl] ester
Other Name:diphosphoric acid, mono[(1alpha,2beta,3alpha,4alpha,5alpha,6beta)-2,3, 4,5,6-pentakis(phosphonooxy)cyclohexyl] ester;5beta[32p] 5Pp-ip5;5beta[32p]-Ip7;5Pp-ip5;Diphosphoinositol pentakisphosphate;Myo-inositol, 1,2,3,4,6-pentakis(dihydrogen phosphate) 5-(trihydrogen diphosphate) (9ci);myo-Inositol, 1,2,3,4,6-pentakis(dihydrogen phosphate) 5-(trihydrogen diphosphate);1-PP-myo-InsP5
CAS No.:149714-25-0
Molecular Formula:C6H19O27P7
InChIKeys:UPHPWXPNZIOZJL-UYSNGIAKSA-N
Molecular Weight:740.02
Exact Mass:739.8277043 g/mol
DSSTox ID:DTXSID00332070
Categories:
Characteristics-
PSA:
447 Ų
Density:2.458±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)
Boiling Point:1246.106±75.00 °C(Press: 760.00 Torr)(predicted)
PKA:1.406±0.10(predicted)
Research-
Class:
GLP-1R agonist
Status:FDA-approved (Ozempic / Wegovy / Rybelsus)
Mechanism:Long-acting, selective glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. Engineered for extended half-life (~1 week) via albumin binding (fatty acid acylation at Lys26) and resistance to DPP-4 degradation (Aib substitution at position 8). Promotes insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite via central nervous system GLP-1R activation.
Activity note:Potent, selective GLP-1R agonist. Reported binding affinity Ki = 0.38 ± 0.06 nM. Semaglutide is a human GLP-1 analog with structural modifications for albumin binding (C18 fatty diacid at Lys26) and enzymatic stability (Aib8 substitution).
Source:Lau J, et al. J Med Chem. 2015;58(18):7370-7380. Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.DOI
Clinical Development:FDA:Ozempic, Wegovy, Rybelsus (approved 2017-12-05)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
NEJM: Wilding et al. (2021) — STEP-1; NEJM: Marso et al. (2016) — SUSTAIN-6; J Med Chem: Lau et al. (2015) — Discovery of Semaglutide; FDA: Ozempic (NDA 209637)
Disclaimer:Semaglutide is approved as a prescription medicine (Ozempic, Wegovy, Rybelsus) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
retatrutide,TB-500,GHK-CU,peptide
-
Location:
1-1, Kailuo Road, Taojia Town, Jiulongpo District, Chongqing
-
Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
501-1000
-
Year of Establishment:
2023
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
